Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-08-07 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the third meeting of the third board of directors of Hangzhou Anjiesi Medical Technology Co., Ltd. It includes approval of the 2025 semi-annual report and related reports, but the actual reports are disclosed separately on the Shanghai Stock Exchange website. The document itself is a board meeting resolution announcement, not the full semi-annual report or financial statements. It does not contain substantive financial data but references other filings. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting decisions and approvals.
2025-08-07 Chinese
安杰思关于公司2025年度提质增效重回报专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度评估报告" (half-year assessment report) related to the company's 2025 "提质增效重回报专项行动方案" (quality improvement and return to investors special action plan). It contains detailed operational, R&D, market, governance, and investor relations information for the first half of 2025. It includes financial data such as R&D expenses, profit distribution plans, dividend payments, and governance updates. The document is comprehensive and contains substantive financial and operational data for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not a brief announcement or a certification letter, nor is it a full annual report or earnings release. Therefore, the best classification is Interim / Quarterly Report (IR). H1 2025
2025-08-07 Chinese
安杰思股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a shareholder's plan to reduce their holdings in the company, including specifics on the number of shares, percentages, methods of reduction, and timing. It includes legal compliance statements and risk disclosures related to the share reduction plan. This type of document is a shareholder reduction or shareholding change notification, which fits the category of Major Shareholding Notification (MRQ). It is not a financial report, earnings release, or management information, but a regulatory announcement about shareholding changes.
2025-07-02 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司差异化权益分派的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsor (中信证券股份有限公司) regarding a differentiated equity distribution by 杭州安杰思医学科技股份有限公司. It discusses share repurchase, employee stock plans, and adjustments to dividend distribution, including specific dates and regulatory references. The document is not a full annual report or earnings release but a formal audit or verification opinion related to a specific financial action (differentiated equity distribution). It is not a brief announcement or a proxy solicitation but a detailed sponsor's verification opinion, which fits the category of an Audit Report / Information (AR). The document length is 3460 characters, which is relatively short but contains substantive verification content rather than just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2024
2025-07-02 Chinese
安杰思2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled '2024年年度权益分派实施公告' which translates to '2024 Annual Equity Distribution Implementation Announcement'. It details the dividend distribution plan for the 2024 fiscal year, including dividend per share, relevant dates (record date, ex-dividend date, payment date), tax treatment, and implementation methods. The document is an announcement of the dividend amount and payment details following the approval at the 2024 Annual General Meeting. It does not contain full financial statements or comprehensive financial performance data, nor is it a report or presentation. The document length is 3753 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2025-07-02 Chinese
安杰思关于2025年员工持股计划非交易过户完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a non-trading transfer of shares related to the company's 2025 employee stock ownership plan. It details the number of shares transferred, the participants, and the plan's terms. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a capital-related event (employee stock ownership plan implementation and share transfer). The document length is short (1325 characters) and it is a formal announcement of a completed transaction related to share ownership. This fits best under Capital/Financing Update (CAP) as it concerns share transfers and employee stock plans, which are capital structure related updates.
2025-06-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.